Format

Send to

Choose Destination
J Affect Disord. 2012 Feb;136(3):1174-8. doi: 10.1016/j.jad.2011.04.059. Epub 2011 Sep 10.

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.

Author information

1
Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. ylevkovich@partners.org

Abstract

BACKGROUND:

Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD.

METHODS:

This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment.

RESULTS:

There was a greater improvement in the ability to recall information (p=0.04) and a trend toward statistical significance for greater improvement in word-finding (p=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance.

CONCLUSION:

These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

PMID:
21911258
DOI:
10.1016/j.jad.2011.04.059
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center